Sign in
ABOS Stock Price, Chart, Stats & News
Acumen Pharmaceuticals, Inc.
Save
Acumen Pharmaceuticals, Inc. (ABOS) does not currently pay a dividend.
135.08M
Market cap
–
Current P/E
–
Forward P/E
ABOS chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -98.78% |
ROE | -111.27% |
D/E | 0.44x |
Interest coverage ratio | -29.32x |
ABOS valuation
P/E | – |
P/S | – |
P/B | 1.94x |
P/CF | -1.18x |
P/FCF | -1.18x |
P/OCF | -1.18x |
PEG | -0.13x |
EV multiple | -1.35x |
About
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers.
Similar securities
Based on sector and market capitalization
Report issue